{
  "docId": "019de075-60f4-719a-882e-3143e28b60e4",
  "docSlug": "fdbc224a3aaf8eece0f490c97a32599d",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 35 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 35,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines clinical trial progress (THIO-101, 102, 103), regulatory designations, and intellectual property status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-60f4-719a-882e-3143e28b60e4/4",
  "deckHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4",
  "deckJsonHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4.json",
  "deckAnchorHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.87,
        "w": 0.32,
        "x": 0.68,
        "y": 0.13
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e16863a-ba5f-40b7-a35b-37ace7938082",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.65,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Telomere-Targeting Agents: THIO in clinic, Advancing pipeline; Efficacy; Safety; FDA: 2 Orphan Drug Designations (HCC and SCLC); REGN: Clinical Supply Agreement; Phase 2 Go-to-Market Accelerated Approval THIO-101 trial in NSCLC underway (Enrolling in AUS and EU, US IND submission targeted for mid-2023, Upcoming Milestones: Dose Selection, ORR, DCR, DoR, PFS); Phase 2 Go-to-Market Accelerated Approval THIO-102 basket/umbrella planned to start in 2023; Phase 2/3 Confirmatory/Expansion THIO-103 basket trial planned to start in 2023; Multiple telomere-targeting compounds designed in-house, 3 filed for patent: MAIA-2021-020, MAIA-2022-012, MAIA-2021-029",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f328b122-e476-4b88-b41d-651a74c40ae0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "INVESTMENT OVERVIEW",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c6889f2-b5bc-44d8-9079-5d221d5a5234",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "d69c9741-73a0-4fb6-8b62-c573f5ccdee6",
      "evidence": "This slide is titled 'INVESTMENT OVERVIEW' and contains a list/bullet of key points, which is typical of an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}